Sangamo’s stock declined 4.3% following the quarter, reflecting investor concerns about the NASDAQ delisting and the continued uncertainty regarding capital availability, which clouds the company’s path to completing the BLA submission and advancing its pipeline.

• The company transitioned to trading on the OTCQB Venture Market after NASDAQ delisting due to minimum bid requirement noncompliance, heightening market uncertainty.
• The rolling BLA submission for ST-920 in Fabry disease is ongoing, with the first 2 modules submitted; completion is contingent on securing additional funding.
• Six clinical sites activated for the Phase I/II STAND study of ST-503 in neuropathic pain, with preclinical safety data published.
• Progress continues on the ST-506 prion disease program, including ongoing GLP toxicology analysis and regulatory discussions with the UK MHRA.
• Sangamo emphasized strategic efforts to raise capital and explore partnerships, underscoring the critical importance of financing to sustain operations and development milestones.